A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Trial Profile

A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2014

At a glance

  • Drugs Enclomifene (Primary)
  • Indications Hypogonadism; Male infertility
  • Focus Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 09 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 May 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014, as per ClinicalTrials.gov record.
    • 23 Jan 2014 According to ClinicalTrials.gov record planned end date changed from 1 Oct 2013 to 1 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top